

Alfred Sandringham Caulfield

REFERRAL TO CAR-T CLINIC

Family Name*		Given Name*		Date of Birth*	
<ul style="list-style-type: none"> • Attach supporting documents as listed below • Your patient will be contacted with appointment details • The CAR-T Clinic is via the Haematology Service. Consultations are bulk billed. 					
Enquiries: Clinic Coordinator - T 0436 456 304					
Patient Details *mandatory fields					
Sex	<input type="checkbox"/> Female <input type="checkbox"/> Male <input type="checkbox"/> Other			Telephone*	
Address					
Medicare No		Reference No		Expiry	
Interpreter needed		<input type="checkbox"/> Yes <input type="checkbox"/> No		Language	
Aboriginal or Torres Strait Islander					
Cultural considerations / special needs					
Contact Person		Name			
		Relationship		Telephone	
Disease characteristics					
B-cell Lymphoma			B-Precursor Acute-Lymphoblastic Leukemia/Lymphoma		
<input type="checkbox"/> CD19+ Diffuse large B-cell lymphoma <input type="checkbox"/> CD19+ Primary mediastinal large B-cell lymphoma <input type="checkbox"/> Grade 3B Follicular lymphoma a. Relapsed after autologous SCT OR b. Relapse or refractory to ≥ 2 prior lines of systemic therapy <input type="checkbox"/> Richter's transformation or transformed follicular lymphoma, marginal zone lymphoma or lymphoplasmacytic lymphoma a. Relapsed or refractory to ≥ 2 lines of systemic therapy administered after transformation			<input type="checkbox"/> CD19+ B-cell acute lymphoblastic leukemia with one of the following: a. Refractory b. Relapsed after allogeneic SCT c. Second or later relapse d. Ineligible for allogeneic SCT Age 18- 25 years inclusive <input type="checkbox"/> Ph+ positive ALL who have failed 2 lines of TKI therapy or TKI is contraindicated		
Patient criteria					
<input type="checkbox"/> WHO Performance status of ≤ 1 <input type="checkbox"/> Renal function: CrCl > 40ml/min <input type="checkbox"/> Liver function: <ul style="list-style-type: none"> ▪ Bilirubin < 2 x ULN (unless Gilbert's syndrome or disease involvement) ▪ ALT or ALT ≤ 5 times the ULN for age 			<input type="checkbox"/> Pulmonary function: SaO ₂ > 91% on RA <input type="checkbox"/> Adequate haematological function <input type="checkbox"/> Cardiac function: <ul style="list-style-type: none"> ▪ NYHA grade < 2 heart failure ▪ LVEF $\geq 40\%$ confirmed on TTE or MUGA 		



Alfred Sandringham Caulfield

REFERRAL TO CAR-T CLINIC

Family Name*		Given Name*		Date of Birth*	
--------------	--	-------------	--	----------------	--

Social criteria

- Full time supervising carer available for at least the first 28 days post CAR-T infusion
- Able to reside within 1hour of the Alfred hospital for the first 28 days post CAR-T infusion
- Complex psychosocial issues that may impact on compliance or patient safety

Exclusion Criteria

- Pregnancy
- HIV infection (for Kymriah only)
- Active uncontrolled Hepatitis B or C infection
- Active CNS involvement (patients with a history of CNS involvement effectively treated are eligible excluding primary CNS lymphoma)
- Active or poorly controlled CNS disorder (including epilepsy, dementia, or CNS involved autoimmune disorder)
- Active uncontrolled GVHD with need for ongoing immunosuppression
- Comorbidities conferring an expected life expectancy of < 5 years
- Live vaccines within 6 weeks of planned CAR-T infusion

Documents required to accompany referral

- Referral letter stating date of diagnosis / transformation, prior lines of treatment and response, and any active or chronic comorbidities
- Medication list
- Recent / relevant PET / CT / MRI Reports (screenshot of PET images if possible)
- Relevant histopathology reports
- Recent FBE and EUC

Note: the above criteria are a guide only and may not be an absolute contraindication to CAR-T Cell treatment. Eligibility will be confirmed following clinical assessment at The Alfred

Referrer Details

Name		Referral date	
Address		Copies to	
Telephone		Email	
Fax		Provider No	

Return referral to: CAR-T.Referrals@alfred.org.au